407 POSTER A single institution randomized trial of taxotere (T) and xeloda (X) given in combination vs. taxotere (t) followed by xeloda (x) after progression as first line chemotherapy (CT) for metastatic breast cancer (MBC)

Randomized Trial ◽

Metastatic Breast ◽

Single Institution ◽

First Line ◽

A Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation after Achieving Clinical Response in Patients with Metastatic Breast Cancer who Received Six Cycles of Gemcitabine Plus Paclitaxel as First-Line Chemotherapy (KCSG-BR 0702, NCT00561119)

Annals of Oncology ◽

10.1016/s0923-7534(20)31928-1 ◽

2012 ◽

Vol 23 ◽

pp. xi6

Author(s):

Y.-H. Im ◽

Y.H. Park ◽

K.H. Jung ◽

S.-A. Im ◽

J.H. Sohn ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Clinical Response ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Multicenter Randomized Trial ◽

Abstract OT1-01-12: A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

10.1158/1538-7445.sabcs16-ot1-01-12 ◽

2017 ◽

Author(s):

YH Park ◽

S-A Im ◽

JH Sohn ◽

KS Lee ◽

YS Chae ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Multicenter Randomized Trial ◽

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00186-6 ◽

2011 ◽

Vol 2011 ◽

pp. 120-121

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Gene ◽

Highly Active ◽

Multicenter Phase ◽

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

Yearbook of Oncology ◽

10.1016/j.yonc.2011.08.012 ◽

2011 ◽

Vol 2011 ◽

pp. 32-33 ◽

Cited By ~ 1

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Gene ◽

Highly Active ◽

Multicenter Phase ◽

Faculty Opinions recommendation of Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998593.793477027 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Disease Control ◽

Randomized Trial ◽

Metastatic Breast ◽

Phase Iii ◽

Maintenance Chemotherapy ◽

First Line ◽

Multicenter Randomized Trial ◽

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can

Cancer Communications ◽

10.1186/s40880-019-0375-7 ◽

2019 ◽

Vol 39 (1) ◽

pp. 29 ◽

Cited By ~ 1

Author(s):

Ji-Yeon Kim ◽

Seri Park ◽

Seock-Ah Im ◽

Sung-Bae Kim ◽

Joohyuk Sohn ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Randomized Trial ◽

Phase Ii ◽

Metastatic Breast ◽

Life Outcomes ◽

First Line ◽

Epirubicin and vinorelbine versus single agent epirubicin as first line chemotherapy in metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80197-6 ◽

2002 ◽

Vol 38 (11) ◽

pp. S66-S67

Author(s):

B Ejlertsen

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

First Line ◽

First line chemotherapy of metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdj974 ◽

2006 ◽

Vol 17 ◽

pp. v165-v168 ◽

Cited By ~ 21

Author(s):

P. Pronzato ◽

M. Rondini

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Cited By ~ 21

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Single Centre ◽

Phase Iii Trial ◽

Luminal-like metastatic breast cancer: which is the room of endocrine maintenance therapy after first line chemotherapy?

Annals of Oncology ◽

10.1093/annonc/mdv336.03 ◽

2015 ◽

Vol 26 ◽

pp. vi3

Author(s):

S. Moroso ◽

M. Bonotto ◽

L. Gerratana ◽

G. Arpino ◽

C. De Angelis ◽

...

Keyword(s):

Breast Cancer ◽

Maintenance Therapy ◽

Metastatic Breast ◽

First Line ◽